Pfizer's plan for $110+ Covid-19 vaccines riles up US senators

Pfizer’s Covid-19 vaccine became the best-selling medical product of all time in 2021, hauling in almost $37 billion in just one year.

But as the Big Pharma has seen sales decline with the changing of the variants and new government funds running dry, the firm’s mRNA vaccine will have to switch over to the commercial market at some point soon, and be covered by insurance. Two key senators are taking issue with that switch, which comes at a much steeper price — at least $110 per jab, rather than $19.50 per dose at the beginning of the pandemic.